Neoplasms

Digestive System Diseases

All Conditions

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

All Drugs and Chemicals

Immunomodulating Agents

Immunologic Factors

Combination of CIK cells and chemotherapy

Combination of CIK cells and immunotherapy

Combination of CIK cells and targeted therapy

CIK in combination with any two or three of these (i.e., chemotherapy, immunotherapy, and targeted therapy) treatments

Combination of chemotherapy and autologous cytokine induced killer cells

CIK combined with chemotherapy group

Combination of immunotherapy and autologous cytokine induced killer cells

CIK combined immunotherapy group

Combination of targeted therapy and autologous cytokine induced killer cells

CIK combined targeted therapy group

CIK combined with any two or three of them (i.e. chemotherapy, immunotherapy and targeted therapy)

CIK in combination with other therapies

shicang yu, M.D. and Ph.D.

This project plans to use CIK combined with chemotherapy, immunotherapy and targeted therapy to treat CRC patients, so as to explore the effectiveness of CIK treatment and the CRC subtypes more suitable for CIK treatment, thereby improving the survival rate and quality of life of CRC patients.

Colorectal cancer (CRC) is a malignant tumor that seriously threatens human health, and according to the international agency for research on cancer (IARC) data, in 2018, the number of new cases of CRC totalled more than 1.8 million and the number of deaths totalled more than 88million, making it the third most common cancer worldwide \[1\]. In recent years, with the development of economic level in China, changes in lifestyle and dietary structure, the incidence and mortality of CRC have shown a continuous increasing trend, and it is ranked 5th in all malignant tumors. According to statistics, at present, our country has 376000 new CRC cases and 191000 deaths annually, and the whole face extremely serious challenges.

Patients with advanced CRC have a more complicated disease, and the 5-year survival rate is even less than 5%. A single therapeutic means cannot achieve the desired therapeutic effect, and often multiple therapeutic modalities are used for intervention, including surgery, radiotherapy, chemotherapy, interventional minimally invasive treatment, immunotherapy and molecular targeting, etc. Because of the potential efficacy of CIK treatment in controlling tumor growth and prolonging patient survival, but there are still few clinical studies about CIK combined with other treatment modalities, this protocol is intended to use CIK combined with chemotherapy, immune and targeted therapy in CRC patients, in order to explore the effectiveness of CIK treatment and more suitable CRC subtypes for CIK treatment, and then improve the survival rate and quality of life of CRC patients.

Clinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer

Treatment of Colorectal Cancer With Autologous Cytokine Induced Killer Cells (CIK)

Disease control rate of colorectal cancer

objective response rate of colorectal cancer

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Clinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer	NCT05676190	Colorectal Canc...	CIK combined wi... CIK combined im... CIK combined ta... CIK in combinat...	18 Years - 70 Years	Southwest Hospital, China
Clinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer	NCT05676190	Colorectal Canc...	CIK combined wi... CIK combined im... CIK combined ta... CIK in combinat...	18 Years - 70 Years	Southwest Hospital, China

Spots Global Cancer Trial Database for cik combined immunotherapy group